JLJoseph LaPorta

Joseph LaPorta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph LaPorta has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Racial Disparities in Longitudinal Functional Outcome After Ischemic Stroke

    by David J. Robinson, Heidi Sucharew, Lili Ding, Rob Stanton, Yasmin Aziz, Paul Wechsler, Lisa Nobel, Brian Stamm, Shea Wright, Joseph Laporta, et al.

    BACKGROUND: The burden of stroke is unequally distributed in the United States, with Black individuals experiencing more incident stroke. It remains unclear whether Black individuals also experience worse stroke recovery. We sought to study disparities in longitudinal functional outcome after acute ischemic stroke in a population-based study. METHODS: We conducted a retrospective cohort study in the Greater Cincinnati Northern Kentucky region over an 18-month period (July 2019 to December 2020). All acute ischemic stroke events were captured. The modified Rankin Scale scores were determined at discharge, 3, 6, and 12 months for patients who survived the index event. We studied the association between Black race and longitudinal modified Rankin Scale (across all time points) with mixed-effects ordinal regression, initially adjusting for age, sex, and time since stroke. Hierarchical regression was used to sequentially adjust for stroke severity and management, premorbid health, and social determinants. RESULTS: Among 2796 patients with acute ischemic stroke (mean age, 69.0; 31% Black; 52% female), 2537 survived and were included (mean age, 68.4; 32% Black; 52% female). Black race was associated with a worse longitudinal modified Rankin Scale score (cOR, 2.61 [95% CI, 1.89–3.60]). Excluding patients with recurrent events did not change this association (cOR, 2.69 [95% CI, 1.92–3.78]). Adding variables reflecting initial stroke severity and management partly attenuated the association (cOR, 1.92 [95% CI, 1.43–2.60]). Adding variables reflecting premorbid health further attenuated the association (cOR decreased to 1.43 [95% CI, 1.09–1.87]). The remaining association between Black race and the modified Rankin Scale score was fully attenuated by social determinants, with cOR, 1.09 (95% CI, 0.80–1.47). There was no interaction between race and time since stroke. CONCLUSIONS: Starting at discharge and persisting out to 12 months, acute ischemic stroke functional outcomes are worse among Black individuals. These disparities are significantly attenuated by clinical factors and social determinants; future studies should explore whether the social determinants can be intervened upon in the recovery period.

  • Case Report: Disseminated Tuberculosis After Kidney Transplantation

    by Ashton D. Hall, Moises A. Huaman, Joseph C. LaPorta, Keith M. Luckett

    : Tuberculosis (TB) can cause significant morbidity and mortality among solid organ transplant (SOT) recipients, including disseminated disease. Most TB cases after SOT occur in kidney transplant recipients, although data about TB in this population are sparse. Tuberculosis may present atypically in immunocompromised patients, underscoring why physicians must maintain high clinical suspicion when pertinent epidemiological risk factors are present, including birth or former residence in a country with endemic TB. We describe a unique case of disseminated TB in a 54-year-old Filipino woman who developed central nervous system tuberculoma, Pott’s disease, chorioretinitis, and a perinephric fluid collection after kidney transplantation. Despite being a preventable and curable disease, TB remains a relevant and challenging infection with complex diagnostic and treatment guidelines.


  • Open Access

    Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment

    by Luca Marsili, Samuel Marcucci, Joseph LaPorta, Martina Chirra, Alberto J. Espay, Carlo Colosimo

    Paraneoplastic neurological syndromes (PNS) include any symptomatic and non-metastatic neurological manifestations associated with a neoplasm. PNS associated with antibodies against intracellular antigens, known as “high-risk” antibodies, show frequent association with underlying cancer. PNS associated with antibodies against neural surface antigens, known as “intermediate- or low-risk” antibodies, are less frequently associated with cancer. In this narrative review, we will focus on PNS of the central nervous system (CNS). Clinicians should have a high index of suspicion with acute/subacute encephalopathies to achieve a prompt diagnosis and treatment. PNS of the CNS exhibit a range of overlapping “high-risk” clinical syndromes, including but not limited to latent and overt rapidly progressive cerebellar syndrome, opsoclonus-myoclonus-ataxia syndrome, paraneoplastic (and limbic) encephalitis/encephalomyelitis, and stiff-person spectrum disorders. Some of these phenotypes may also arise from recent anti-cancer treatments, namely immune-checkpoint inhibitors and CAR T-cell therapies, as a consequence of boosting of the immune system against cancer cells. Here, we highlight the clinical features of PNS of the CNS, their associated tumors and antibodies, and the diagnostic and therapeutic strategies. The potential and the advance of this review consists on a broad description on how the field of PNS of the CNS is constantly expanding with newly discovered antibodies and syndromes. Standardized diagnostic criteria and disease biomarkers are fundamental to quickly recognize PNS to allow prompt treatment initiation, thus improving the long-term outcome of these conditions.


  • The man behind the bed: a case of peduncular hallucinosis treated with quetiapine and melatonin

    by Joseph LaPorta, Robert Stanton, Adam Koss

    An 81-year-old female presented with a right pontine infarct and later developed recurrent vivid hallucinations. After a workup for delirium and hallucinosis was unrevealing, a diagnosis of peduncular hallucinosis (PH) was proposed. Treatment with quetiapine and, later, adjunctive nightly melatonin resulted in return to cognitive baseline. An array of etiologies can be responsible for visual hallucinations, including PH. Herein, we review several disorders of hallucinosis and their diagnostic workup. Additionally, we explore the pathophysiology of PH and its association with the pontine-geniculate-occipital (PGO) pathway and propose why correction of the sleep-wake cycle may benefit patients with PH.